It seems 2025 was the year the UK's Competition and Markets Authority (CMA) decided to channel their inner "yes person." In what can only be described as a complete personality makeover, the notoriously stern competition watchdog didn't block a single merger deal all year long. You read that right - zero, zilch, nada! It's the first time since 2017 that they've been this agreeable, giving every single transaction that knocked on their door a cheerful thumbs up. So what sparke

In what's shaping up to be the pharmaceutical industry's version of "The Great Escape," Japan's drugmakers are abandoning public markets faster than patients fleeing a dentist's office, with Hisamitsu Pharmaceutical leading this dramatic exodus with a jaw-dropping ¥457 billion ($2.9 billion) disappearing act. CEO Kazuhide Nakatomi apparently decided that public market scrutiny was causing more stress than his company's signature pain-relief patches could handle. The announcem